Jin Ting-Yu, Rong Pei-Qing, Liang Hai-Yong, Zhang Pei-Pei, Zheng Guo-Qing, Lin Yan
Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Front Pharmacol. 2020 Jul 17;11:1031. doi: 10.3389/fphar.2020.01031. eCollection 2020.
Fatigue, as a complex, multidimensional symptom, is associated with many physical illnesses. C. A. Mey (PG) is an important herbal drug which has been used for benefiting Qi for thousand years. C. A. Mey and its compounds (PGC) possess various pharmacological activities, including anti-fatigue. Here, we conducted a systematic review of both randomized clinical trials (RCTs) and preclinical animal studies to investigate the efficacy and safety of PGC for fatigue.
Electronic searches were performed in 7 databases from the time of each database's inception to August 2019. The methodological quality of RCTs was assessed using 7-item checklist recommended by Cochrane Collaboration or by the CAMARADES 10-item quality checklist. All the data were analyzed using Rev-Man 5.3 and Stata SE software.
Eight eligible RCTs and 30 animal studies were identified. The risk of bias scores in RCTs ranged from 4/7 to 7/7, and of animal studies varied from 4/10 to 7/10. Meta-analyses showed that PGC was superior to placebo according to their respective fatigue scales, heart rate recovery, and clinical effect (P < 0.05). There were a similar number of adverse effects between PGC and placebo group (P > 0.05). Meta-analyses showed that PGC can significantly decrease level of blood lactate, blood urea nitrogen, creatine kinase, malondialdehyde, and lactic dehydrogenase in serum, level of malondialdehyde in liver and level of gamma-aminobutyric acid, 5-hydroxytryptamine in brain tissue, and increase swimming time, level of glutathione peroxidase, glucose, superoxide dismutase in serum, level of glycogen and activity of superoxide dismutase, glutathione peroxidase, and catalase in skeletal muscle, level of hepatic glycogen in liver and level of dopamine, acetylcholine in brain tissue, compared with control (P < 0.05). Meta-analyses showed no significant difference in animal body weight between PGC and control (P > 0.05).
The present findings supported, to a certain degree, that PGC can be recommended for routine use in fatigue. The possible mechanism of PGC resists fatigue, mainly through antioxidant stress, regulating carbohydrate metabolism, delaying the accumulation of metabolites, promoting mitochondrial function, neuroprotection, antiapoptosis, and regulating neurotransmitter disorder in central nervous system.
疲劳作为一种复杂的多维度症状,与许多身体疾病相关。C. A. Mey(PG)是一种重要的草药,已被用于益气千年。C. A. Mey及其化合物(PGC)具有多种药理活性,包括抗疲劳作用。在此,我们对随机临床试验(RCT)和临床前动物研究进行了系统评价,以研究PGC治疗疲劳的疗效和安全性。
从每个数据库建立之时至2019年8月,在7个数据库中进行电子检索。使用Cochrane协作网推荐的7项清单或CAMARADES 10项质量清单评估RCT的方法学质量。所有数据使用Rev-Man 5.3和Stata SE软件进行分析。
确定了8项符合条件的RCT和30项动物研究。RCT中的偏倚风险评分范围为4/7至7/7,动物研究的偏倚风险评分范围为4/10至7/10。Meta分析表明,根据各自的疲劳量表、心率恢复情况和临床效果,PGC优于安慰剂(P < 0.05)。PGC组和安慰剂组的不良反应数量相似(P > 0.05)。Meta分析表明,与对照组相比,PGC可显著降低血清中血乳酸、血尿素氮、肌酸激酶、丙二醛和乳酸脱氢酶水平,肝脏中丙二醛水平,脑组织中γ-氨基丁酸、5-羟色胺水平,并增加游泳时间、血清中谷胱甘肽过氧化物酶、葡萄糖、超氧化物歧化酶水平,骨骼肌中糖原水平以及超氧化物歧化酶、谷胱甘肽过氧化物酶和过氧化氢酶活性,肝脏中肝糖原水平以及脑组织中多巴胺、乙酰胆碱水平(P < 0.05)。Meta分析表明,PGC与对照组之间动物体重无显著差异(P > 0.05)。
本研究结果在一定程度上支持PGC可推荐用于疲劳的常规治疗。PGC抗疲劳的可能机制主要是通过抗氧化应激、调节碳水化合物代谢、延缓代谢产物积累、促进线粒体功能、神经保护、抗凋亡以及调节中枢神经系统神经递质紊乱。